144 related articles for article (PubMed ID: 35668339)
1. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Sánchez Cánovas M; Fernández Garay D; Adoamnei E; Guirao García E; López Robles J; Cacho Lavin D; Martínez de Castro E; Campos Balea B; Garrido Fernández A; Fernández Pérez I; Ferrández Arias A; Suarez N; Quintanar Verduguez T; Lobo de Mena M; Rodríguez L; Gutierrez D; Martín Fernández de Soiginie AM; García Adrián S; Ferrer Pérez AI; Delgado Heredia MJ; Muñoz Lerma A; Luque R; Mazariegos Rubí M; Rúperez Blanco AB; García Escobar I; Mendiola J; Muñoz Martín AJ
Clin Transl Oncol; 2023 Oct; 25(10):3021-3031. PubMed ID: 37036596
[TBL] [Abstract][Full Text] [Related]
3. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
7. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
8. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
9. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
[TBL] [Abstract][Full Text] [Related]
10. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.
Stadler JC; Keller L; Mess C; Bauer AT; Koett J; Geidel G; Heidrich I; Vidal-Y-Sy S; Andreas A; Stramaglia C; Sementsov M; Haberstroh W; Deitert B; Hoehne IL; Reschke R; Haalck T; Pantel K; Gebhardt C; Schneider SW
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258039
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
[TBL] [Abstract][Full Text] [Related]
13. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.
Giustozzi M; Becattini C; Roila F; Agnelli G; Mandalà M
Cancer Treat Rev; 2021 Nov; 100():102280. PubMed ID: 34438237
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors for cancer and venous thromboembolic events.
Gong J; Drobni ZD; Alvi RM; Murphy SP; Sullivan RJ; Hartmann SE; Gilman HK; Lee H; Zubiri L; Raghu VK; Karp-Leaf RS; Zafar A; Zlotoff DA; Frigault MJ; Reynolds KL; Neilan TG
Eur J Cancer; 2021 Oct; 158():99-110. PubMed ID: 34662835
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
17. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
18. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
20. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
